查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1339255

麻風病治療藥物市場,份額,規模,趨勢,行業分析報告:按藥物類別,疾病類型,給藥途徑,分銷管道,地區,細分市場,預測2023-2032年

Leprosy Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class ; By Disease Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 112 Pages | 商品交期: 最快1-2個工作天內

價格

根據Polaris Market Research的最新研究顯示，到2032年，全球麻風病藥物市場規模預計將達到50.33億美元。該報告提供了對當前市場動態的詳細見解，並對未來市場成長進行了分析。

由於皮膚病的盛行率不斷增加，對治療麻風病的藥物的需求正在迅速擴大。在中國和印度等國家，牛皮癬和麻風病等皮膚病的盛行率正在增加，這推動了市場的發展。根據世界衛生組織 (WHO) 統計，大約 120 個國家出現麻風病例，每年報告病例超過 20 萬例。數億人受到皮膚 NTD 的影響。

此外，麻風病作為一種被忽視的熱帶疾病，損害了邊緣人群（主要生活在偏遠農村地區）的生活水平，造成難以言喻的不適、痛苦、恥辱和心理困擾。由於發病率高，世界上一些地區的發生率和傳播率都很高。世界衛生組織估計，在過去 20 年裡，大約有 1,600 萬名麻風病患者接受了治療。因此，皮膚病患病率的上升和 NTD 的盛行率增加了對麻風病藥物的需求，推動了預測期內的市場成長。

據世界衛生組織稱，過去十年需要接受被忽視熱帶疾病幹預的人數減少了 25%，2020 年至 2021 年將減少約 8,000 萬人。此外，以殘障壽命衡量的疾病負擔也持續下降。2016年至2019年，每年有超過10億人接受治療。到 2022 年底，47 個國家已消除至少一種被忽視的熱帶疾病。

然而，新冠肺炎 (COVID-19) 疫情嚴重影響了 NTD 項目，導致社區幹預措施的實施減少、醫療機構提供的服務以及醫療用品供應鏈的獲取受到限制，導致這一良好趨勢崩潰。因此，從 2019 年到 2020 年，接受 NTD 治療的人數減少了 34%。

麻風病治療藥物市場報告亮點

由於氨苯□是治療痲瘋病的第一線藥物，注射給藥途徑部分預計在預測期內將以顯著的複合年增長率成長。

預計抗結核藥物在預測期內將佔很大的市場份額，因為利福平等藥物可治療結核病和痲瘋病。

由於患病率上升以及政府支持治療的計劃，預計亞太地區在預測期內將以顯著的複合年增長率增長。

目錄

第 1 章 簡介

第二章執行摘要

第三章研究方法論

第四章 全球麻風病藥物市場洞察

  • 痲瘋治療 - 產業概況
  • 麻風病藥物市場動態
    • 驅動因素和機遇
      • 技術進步
      • 麻風病藥物技術在醫療保健中的使用增加
    • 限制因素和挑戰
      • 數位化程度的提高限制了市場成長
  • PESTLE分析
  • 麻風病藥物產業的趨勢
  • 價值鏈分析
  • COVID-19 感染的影響分析

第五章 全球麻風病藥物市場（依藥物類別）

  • 主要發現
  • 介紹
  • 抗菌劑
  • 麻風
  • □
  • 賴氨酸
  • 抗結核藥
  • 其他

第六章全球麻風病治療藥物市場（依疾病類型）

  • 主要發現
  • 介紹
  • 儲袋細菌性痲瘋病
  • 多種微生物麻風病

第七章 全球麻風病藥物市場（依給藥途徑）

  • 主要發現
  • 介紹
  • 口服
  • 注射
  • 當地的

第八章全球漢森疾病治療藥物市場（按分銷管道）

  • 主要發現
  • 介紹
  • 醫院藥房
  • 零售藥店
  • 藥店
  • 網上藥店

第九章全球麻風病治療藥物市場（按地區）

  • 主要發現
  • 介紹
    • 2019-2032 年麻風病治療藥物市場評估（按地區）
  • 麻風病藥物市場 - 北美
    • 北美：麻風病藥物市場，依藥物類別，2019-2032
    • 北美：麻風病治療藥物市場，依通路劃分，2019-2032
    • 北美：麻風病藥物市場，依疾病類型劃分，2019-2032 年
    • 北美：麻風病藥物市場，依給藥途徑劃分，2019-2032 年
    • 麻風病治療藥物市場—美國
    • 麻風病藥物市場 - 加拿大
  • 麻風病藥物市場－歐洲
    • 歐洲：麻風病藥物市場，依藥物類別，2019-2032 年
    • 歐洲：麻風病藥物市場，依通路劃分，2019-2032 年
    • 歐洲：麻風病藥物市場，依疾病類型劃分，2019-2032 年
    • 歐洲：麻風病藥物市場，依給藥途徑，2019-2032
    • 痲瘋病藥物市場 - 英國
    • 麻風病藥品市場—法國
    • 麻風病藥品市場—德國
    • 麻風病藥品市場－義大利
    • 麻風病藥品市場－西班牙
    • 麻風病藥物市場－荷蘭
    • 麻風病藥品市場－俄羅斯
  • 麻風病藥物市場 - 亞太地區
    • 亞太地區：2019-2032 年痲瘋病藥物市場（依藥物類別）
    • 亞太地區：痲瘋病藥物市場，依通路劃分，2019-2032 年
    • 亞太地區：痲瘋病藥物市場，依疾病類型，2019-2032
    • 亞太地區：痲瘋病藥物市場，依給藥途徑劃分，2019-2032 年
    • 痲瘋病藥物市場—中國
    • 麻風病藥物市場 - 印度
    • 漢森病治療藥物市場—日本
    • 麻風病藥物市場 - 馬來西亞
    • 麻風病藥物市場—印度尼西亞
    • 漢森病治療藥物市場—韓國
  • 痲瘋病藥物市場—中東和非洲
    • 中東和非洲：2019-2032 年麻風病藥物市場（依藥物類別）
    • 中東和非洲：2019-2032 年麻風病藥物市場（按分銷管道）
    • 中東和非洲：2019-2032 年麻風病藥物市場（按疾病類型）
    • 中東和非洲：2019-2032 年麻風病藥物市場（依給藥途徑）
    • 麻風病藥物市場－沙烏地阿拉伯
    • 痲瘋病藥物市場－南非
    • 痲瘋病藥物市場－以色列
    • 痲瘋病藥物市場－阿拉伯聯合大公國
  • 痲瘋病藥物市場－拉丁美洲
    • 拉丁美洲：2019-2032 年痲瘋病藥物市場（依藥物類別）
    • 拉丁美洲：麻風病藥物市場，依通路劃分，2019-2032 年
    • 拉丁美洲：2019-2032 年麻風病藥物市場（依疾病類型）
    • 拉丁美洲：麻風病藥物市場，依給藥途徑劃分，2019-2032 年
    • 麻風病藥品市場—墨西哥
    • 麻風病藥物市場－巴西
    • 痲瘋病藥品市場－阿根廷

第10章競爭格局

  • 擴張和收購分析
    • 擴張
    • 獲得
  • 夥伴關係/協作/協議/揭露
  • Acme Pharmaceuticals
  • Astra Zeneca
  • Bayer
  • Bristol-Myers
  • Cadila Pharmaceuticals
  • Eli Lily
  • Genetic Pharma
  • GSK
  • IDPL
  • Johnson & Johnson
  • Lark Laboratories
  • Merck
  • Macleods Pharmaceuticals
  • Novartis
  • Pfizer
  • Systopic Laboratories
  • Sanofi
  • Teva Pharmaceutical
Product Code: PM3635

The global Leprosy Treatment market size is expected to reach USD 5,000.33 million by 2032, according to a new study by Polaris Market Research. The report "Leprosy Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Antibacterial, Leprostatics, Sulfone, Phenazine, Anti-tubercular Drugs, and Others); By Disease Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2023- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The demand for leprosy treatment is growing more quickly due to the increasing incidence of skin diseases. The prevalence of skin conditions like psoriasis and leprosy has increased in nations like China and India, which has fueled the market. According to the World Health Organization, around 120 countries have leprosy cases, and more than 200,000 cases are reported yearly. Hundreds of millions of people have skin NTDs.

Additionally, leprosy, an NTD, hurts the standard of living of mainly marginalized populations in remote rural areas and causes immense discomfort, suffering, stigmatization, and mental distress. The prevalence of high occurrences provides that some regions of the world experience both high incidence and high transmission rates. In the past 20 years, the WHO estimates that approximately 16 million leprosy cases have been treated. Therefore, the rising prevalence of skin disease and NTD prevalence has increased the demand for leprosy treatment, driving the market's growth over the forecast period.

As per the WHO, the number of people needing interventions for NTDs has fallen by 25% over the past ten years, by about 80 million people between 2020 and 2021. Additionally, there is a consistent decline in the disease burden measured in years of life with a disability. Between 2016 and 2019, more than one billion individuals received treatment annually. By the end of 2022, 47 nations had eliminated at least one NTD.

However, the COVID-19 pandemic severely affected NTD programs, which resulted in a decrease in the implementation of community-based interventions, a restriction on access to services provided by healthcare facilities, and negative effects on the supply chains for medical supplies, disrupting this promising trend. As a result, between 2019 and 2020, 34% fewer people were treated for NTDs.

Leprosy Treatment Market Report Highlights

The injectable route of administration segment is anticipated to grow at a significant CAGR over the forecast period owing to the drug of first preference for treating leprosy being dapsone.

Anti-tubercular drugs are expected to hold a significant market share over the forecast period due to drugs such as Rifampin treating both TB and leprosy.

Asia-Pacific is expected to grow at a considerable CAGR over the projected period on account of the rising disease prevalence as well as the government programs to support the treatment.

The global players include: Astra Zeneca, Bayer, GSK, Johnson & Johnson, Merck, Pfizer Inc., Systopic Laboratories, Sanofi, and Teva Pharmaceutical.

Polaris Market Research has segmented the Leprosy Treatment market report based on drug class, route of administration, disease type, distribution channel, and region:

Leprosy Treatment, Drug Class Outlook (Revenue - USD Million, 2019 - 2032)

  • Antibacterial
  • Leprostatics
  • Sulfone
  • Phenazine
  • Anti-tubercular Drugs
  • Others

Leprosy Treatment, Route of Administration Outlook (Revenue - USD Million, 2019 - 2032)

  • Oral
  • Injectable
  • Topical

Leprosy Treatment, Disease Type Outlook (Revenue - USD Million, 2019 - 2032)

  • Paucibacillary Leprosy
  • Multibacillary Leprosy

Leprosy Treatment, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Leprosy Treatment, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Leprosy Treatment Market Insights

  • 4.1. Leprosy Treatment - Industry Snapshot
  • 4.2. Leprosy Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Technological advancement
      • 4.2.1.2. Increasing use of Leprosy Treatment technology in healthcare
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Increasing digitization will restrict the market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Leprosy Treatment Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Leprosy Treatment Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • 5.3. Antibacterial
    • 5.3.1. Global Leprosy Treatment Market, by Antibacterial, by Region, 2019-2032 (USD Million)
  • 5.4. Leprostatics
    • 5.4.1. Global Leprosy Treatment Market, by Leprostatics, by Region, 2019-2032 (USD Million)
  • 5.5. Sulfone
    • 5.5.1. Global Leprosy Treatment Market, by Sulfone, by Region, 2019-2032 (USD Million)
  • 5.6. Phenazine
    • 5.6.1. Global Leprosy Treatment Market, by Phenazine, by Region, 2019-2032 (USD Million)
  • 5.7. Anti-tubercular Drugs
    • 5.7.1. Global Leprosy Treatment Market, by Anti-tubercular Drugs, by Region, 2019-2032 (USD Million)
  • 5.8. Others
    • 5.8.1. Global Leprosy Treatment Market, by Others, by Region, 2019-2032 (USD Million)

6. Global Leprosy Treatment Market, by Disease Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • 6.3. Paucibacillary Leprosy
    • 6.3.1. Global Leprosy Treatment Market, by Paucibacillary Leprosy, by Region, 2019-2032 (USD Million)
  • 6.4. Multibacillary Leprosy
    • 6.4.1. Global Leprosy Treatment Market, by Multibacillary Leprosy, by Region, 2019-2032 (USD Million)

7. Global Leprosy Treatment Market, by Route of Administration

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • 7.3. Oral
    • 7.3.1. Global Leprosy Treatment Market, by Oral, by Region, 2019-2032 (USD Million)
  • 7.4. Injectable
    • 7.4.1. Global Leprosy Treatment Market, by Injectable, by Region, 2019-2032 (USD Million)
  • 7.5. Topical
    • 7.5.1. Global Leprosy Treatment Market, by Topical, by Region, 2019-2032 (USD Million)

8. Global Leprosy Treatment Market, by Distribution Channel

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.3. Hospital Pharmacies
    • 8.3.1. Global Leprosy Treatment Market, by Hospital Pharmacies, by Region, 2019-2032 (USD Million)
  • 8.4. Retail Pharmacies
    • 8.4.1. Global Leprosy Treatment Market, by Retail Pharmacies, by Region, 2019-2032 (USD Million)
  • 8.5. Drug Stores
    • 8.5.1. Global Leprosy Treatment Market, by Drug Stores, by Region, 2019-2032 (USD Million)
  • 8.6. Online Pharmacies
    • 8.6.1. Global Leprosy Treatment Market, by Online Pharmacies, by Region, 2019-2032 (USD Million)

9. Global Leprosy Treatment Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Leprosy Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
  • 9.3. Leprosy Treatment Market - North America
    • 9.3.1. North America: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
    • 9.3.2. North America: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.3.3. North America: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
    • 9.3.4. North America: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.3.5. Leprosy Treatment Market - U.S.
      • 9.3.5.1. U.S.: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.3.5.2. U.S.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.3.5.3. U.S.: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.3.5.4. U.S.: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.3.6. Leprosy Treatment Market - Canada
      • 9.3.6.1. Canada: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.3.6.2. Canada: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.3.6.3. Canada: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.3.6.4. Canada: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • 9.4. Leprosy Treatment Market - Europe
    • 9.4.1. Europe: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
    • 9.4.2. Europe: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.4.3. Europe: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
    • 9.4.4. Europe: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.5. Leprosy Treatment Market - UK
      • 9.4.5.1. UK: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.5.2. UK: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.5.3. UK: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.5.4. UK: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.6. Leprosy Treatment Market - France
      • 9.4.6.1. France: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.6.2. France: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.6.3. France: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.6.4. France: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.7. Leprosy Treatment Market - Germany
      • 9.4.7.1. Germany: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.7.2. Germany: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.7.3. Germany: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.7.4. Germany: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.8. Leprosy Treatment Market - Italy
      • 9.4.8.1. Italy: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.8.2. Italy: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.8.3. Italy: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.8.4. Italy: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.9. Leprosy Treatment Market - Spain
      • 9.4.9.1. Spain: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.9.2. Spain: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.9.3. Spain: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.9.4. Spain: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.10. Leprosy Treatment Market - Netherlands
      • 9.4.10.1. Netherlands: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.10.2. Netherlands: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.10.3. Netherlands: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.10.4. Netherlands: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.11. Leprosy Treatment Market - Russia
      • 9.4.11.1. Russia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.11.2. Russia.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.11.3. Russia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.11.4. Russia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • 9.5. Leprosy Treatment Market - Asia Pacific
    • 9.5.1. Asia Pacific: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
    • 9.5.2. Asia Pacific: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.5.3. Asia Pacific: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
    • 9.5.4. Asia Pacific: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.5.5. Leprosy Treatment Market - China
      • 9.5.5.1. China: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.5.5.2. China.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.5.5.3. China: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.5.5.4. China: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.5.6. Leprosy Treatment Market - India
      • 9.5.6.1. India: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.5.6.2. India.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.5.6.3. India: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.5.6.4. India: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.5.7. Leprosy Treatment Market - Japan
      • 9.5.7.1. Japan: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.5.7.2. Japan.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.5.7.3. Japan: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.5.7.4. Japan: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.5.8. Leprosy Treatment Market - Malaysia
      • 9.5.8.1. Malaysia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.5.8.2. Malaysia.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.5.8.3. Malaysia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.5.8.4. Malaysia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.5.9. Leprosy Treatment Market - Indonesia
      • 9.5.9.1. Indonesia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.5.9.2. Indonesia.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.5.9.3. Indonesia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.5.9.4. Indonesia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.5.10. Leprosy Treatment Market - South Korea
      • 9.5.10.1. South Korea: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.5.10.2. South Korea.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.5.10.3. South Korea: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.5.10.4. South Korea: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • 9.6. Leprosy Treatment Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
    • 9.6.2. Middle East & Africa: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.6.3. Middle East & Africa: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
    • 9.6.4. Middle East & Africa: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.6.5. Leprosy Treatment Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.6.5.2. Saudi Arabia: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.6.5.3. Saudi Arabia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.6.5.4. Saudi Arabia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.6.6. Leprosy Treatment Market - South Africa
      • 9.6.6.1. South Africa: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.6.6.2. South Africa: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.6.6.3. South Africa: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.6.6.4. South Africa: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.6.7. Leprosy Treatment Market - Israel
      • 9.6.7.1. Israel: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.6.7.2. Israel: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.6.7.3. Israel: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.6.7.4. Israel: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.6.8. Leprosy Treatment Market - UAE
      • 9.6.8.1. UAE: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.6.8.2. UAE: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.6.8.3. UAE: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.6.8.4. UAE: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • 9.7. Leprosy Treatment Market - Latin America
    • 9.7.1. Latin America: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
    • 9.7.2. Latin America: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.7.3. Latin America: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
    • 9.7.4. Latin America: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.7.5. Leprosy Treatment Market - Mexico
      • 9.7.5.1. Mexico: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.7.5.2. Mexico: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.7.5.3. Mexico: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.7.5.4. Mexico: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.7.6. Leprosy Treatment Market - Brazil
      • 9.7.6.1. Brazil: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.7.6.2. Brazil: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.7.6.3. Brazil: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.7.6.4. Brazil: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.7.7. Leprosy Treatment Market - Argentina
      • 9.7.7.1. Argentina: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.7.7.2. Argentina: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.7.7.3. Argentina: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.7.7.4. Argentina: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions
  • 11.1. Acme Pharmaceuticals
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Astra Zeneca
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Bayer
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Bristol-Myers
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Cadila Pharmaceuticals
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Eli Lily
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Genetic Pharma
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. GSK
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. IDPL
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Johnson & Johnson
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Lark Laboratories
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Merck
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
  • 11.13.Macleods Pharmaceuticals
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Benchmarking
    • 11.13.4. Recent Development
  • 11.14. Novartis
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Benchmarking
    • 11.14.4. Recent Development
  • 11.15. Pfizer
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Benchmarking
    • 11.15.4. Recent Development
  • 11.16. Systopic Laboratories
    • 11.16.1. Company Overview
    • 11.16.2. Financial Performance
    • 11.16.3. Product Benchmarking
    • 11.16.4. Recent Development
  • 11.17. Sanofi
    • 11.17.1. Company Overview
    • 11.17.2. Financial Performance
    • 11.17.3. Product Benchmarking
    • 11.17.4. Recent Development
  • 11.18. Teva Pharmaceutical
    • 11.18.1. Company Overview
    • 11.18.2. Financial Performance
    • 11.18.3. Product Benchmarking
    • 11.18.4. Recent Development

List of Tables

  • Table 1 Global Leprosy Treatment Market, by Drug Class, by Region, 2019-2032 (USD Million)
  • Table 2 Global Leprosy Treatment Market, by Disease Type, by Region, 2019-2032 (USD Million)
  • Table 3 Global Leprosy Treatment Market, by Route of Administration, by Region, 2019-2032 (USD Million)
  • Table 4 Global Leprosy Treatment Market, by Distribution Channel, by Region, 2019-2032 (USD Million)
  • Table 5 Leprosy Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 6 North America: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 7 North America: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 8 North America: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 9 North America: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 10 U.S.: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 11 U.S.: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 12 U.S.: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 13 U.S.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 14 Canada: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 15 Canada: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 16 Canada: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 17 Canada: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 18 Europe: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 19 Europe: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 20 Europe: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 21 Europe: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 22 Germany: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 23 Germany: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 24 Germany: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 25 Germany: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 26 France: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 27 France: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 28 France: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 29 France: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 30 UK: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 31 UK: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 32 UK: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 33 UK: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 34 Italy: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 35 Italy: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 36 Italy: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 37 Italy: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 38 Netherlands: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 39 Netherlands: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 40 Netherlands: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 41 Netherlands: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 42 Spain: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 43 Spain: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 44 Spain: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 45 Spain: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 46 Russia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 47 Russia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 48 Russia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 49 Russia: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 50 Asia Pacific: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 51 Asia Pacific: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 52 Asia Pacific: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 53 Asia Pacific: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 54 China: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 55 China: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 56 China: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 57 China: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 58 Japan: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 59 Japan: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 60 Japan: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 61 Japan: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 62 India: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 63 India: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 64 India: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 65 India: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 66 Indonesia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 67 Indonesia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 68 Indonesia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 69 Indonesia: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 70 Malaysia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 71 Malaysia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 72 Malaysia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 73 Malaysia: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 74 South Korea: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 75 South Korea: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 76 South Korea: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 77 South Korea: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 78 Latin America: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 79 Latin America: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 80 Latin America: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 81 Latin America: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 82 Brazil: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 83 Brazil: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 84 Brazil: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 85 Brazil: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 86 Mexico: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 87 Mexico: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 88 Mexico: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 89 Mexico: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 90 Argentina: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 91 Argentina: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 92 Argentina: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 93 Argentina: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 94 Middle East & Africa: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 95 Middle East & Africa: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 96 Middle East & Africa: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 97 Middle East & Africa: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 98 UAE: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 99 UAE: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 100 UAE: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 101 UAE: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 102 Saudi Arabia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 103 Saudi Arabia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 104 Saudi Arabia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 105 Saudi Arabia: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 106 South Africa: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 107 South Africa: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 108 South Africa: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 109 South Africa: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 110 Israel: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 111 Israel: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 112 Israel: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 113 Israel: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)

List of Figures

  • Figure 1. Global Leprosy Treatment Market, 2019-2032 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Distribution Channel
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Drug Class
  • Figure 7. Global Leprosy Treatment Market, by Drug Class, 2021 & 2030 (USD Million)
  • Figure 8. Market by Distribution Channel
  • Figure 9. Global Leprosy Treatment Market, by Distribution Channel, 2021 & 2030 (USD Million)
  • Figure 10. Market by Disease Type
  • Figure 11. Global Leprosy Treatment Market, by Disease Type, 2021 & 2030 (USD Million)
  • Figure 12. Market by Route of Administration
  • Figure 13. Global Leprosy Treatment Market, by Route of Administration, 2021 & 2030 (USD Million)